TP53 and teratoma: This makes this target very appealing from a biological point of view, since p53 pathway is activated specifically in the (miR-371a-3p-negative) teratoma [68], as opposed to the other (malignant) GCT components, which show clear upregulation of miR-371a-3p, leading to inactivation of the p53 pathway [69].